EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib

BACKGROUND: Osimertinib has become standard therapy of advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients and T790M-mediated resistance. We investigated the clinical utility of EGFR mutation tracking in plasma-based circulating tumor DNA (ctDNA) afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Buder, Anna, Hochmair, Maximilian J., Setinek, Ulrike, Pirker, Robert, Filipits, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225165/
https://www.ncbi.nlm.nih.gov/pubmed/32420063
http://dx.doi.org/10.21037/tlcr.2020.03.02

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225165/
https://www.ncbi.nlm.nih.gov/pubmed/32420063
http://dx.doi.org/10.21037/tlcr.2020.03.02

Ejemplares similares